Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rituximab (RTX) for IgG4-related Disease (IgG4-RD): a Prospective,Open-label Trial

NCT01584388 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT01584388
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01584388 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rituximab (RTX) for IgG4-related Disease (IgG4-RD): a Prospective,Open-label Trial
Lead sponsor
Massachusetts General Hospital
Phase
Phase 1/2
Overall status
Completed
Start date
April 30, 2012
Completion date
January 31, 2015
Enrollment
30 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune pancreatitis, pseudotumor, retroperitoneal fibrosis, sialadenitis